There is a high rate of failure in Alzheimer's disease (AD) drug development with 99% of
trials showing no drug-placebo difference. This low rate of success delays new treatments …

The blood-brain barrier, while fundamental in maintaining homeostasis in the central
nervous system, is a bottleneck to achieving efficacy for numerous therapeutics. Improved …

We performed a 15-year post-mortem neuropathological follow-up of patients in the first trial
of amyloid-β immunotherapy for Alzheimer's disease. Twenty-two participants of a clinical …

The identification of amyloid-β precursor protein (APP) pathogenic mutations in familial early
onset Alzheimer's disease (AD), along with knowledge that amyloid-β (Aβ) was the principle …

Biomarkers have a key role in Alzheimer's disease (AD) drug development. Biomarkers can
assist in diagnosis, demonstrate target engagement, support disease modification, and …

Background: Cerebrovascular disease is a common comorbidity in patients with Alzheimer's
disease (AD). It is believed to contribute additively to the cognitive impairment and to lower …

Amyloid‐β transmission has been described in patients both with and without iatrogenic
Creutzfeldt–Jakob disease; however, there is little information regarding the clinical impact …

Objective Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β‐
amyloid fragments leading to cerebrovascular dysfunction and other brain injuries. This …

Objective To describe the prevalence of cerebral microbleeds (CMBs) and determine the
association between CMBs and β-amyloid burden on PET. Methods From the population …

Alzheimer's disease (AD) was discovered and the pathological hallmarks were revealed
more than a century ago. Subsequently, many remarkable discoveries and breakthroughs …